Skip to main content

Table 2 Reasons for exclusion of publications

From: Gadolinium-enhanced cardiovascular magnetic resonance: administered dose in relationship to united states food and drug administration (FDA) guidelines

 

2004

2005

2006

2007

2008

2009

2010

Total

Phantom or animal model

0 (0)

2 (8)

5 (20)

4 (21)

5 (15.6)

6 (17.7)

4 (21)

26 (15.7)

No weight-based contrast dose

2 (16.7)

9 (36)

5 (20)

3 (15.8)

6 (18.7)

8 (23.5)

1 (5.2)

34 (20.4)

Case reports

3 (25)

3 (12)

5 (20)

3 (15.8)

7 (21.9)

8 (23.5)

5 (26.4)

34 (20.4)

Review articles

1 (8.3)

2 (8)

2 (8)

5 (26.4)

7 (21.9)

6 (17.7)

4 (21)

27 (16.3)

Editorials

4 (33.3)

5 (20)

4 (16)

0 (0)

0 (0)

2 (5.8)

0 (0)

15 (9.1)

MRA

2 (16.7)

4 (16)

4 (16)

4 (21)

7 (21.9)

4 (11.8)

5 (26.4)

30 (18.1)

Total

12 (100)

25 (100)

25 (100)

19 (100)

32 (100)

34 (100)

19 (100)

166 (100)

  1. MRA, magnetic resonance angiography. Data is presented as number and percentages.